NO331789B1 - Farmasoytisk og/eller kosmetisk sammensetning for behandling av lokale adipositter og/eller cellulitt og fremgangsmate for kosmetisk behandling derav - Google Patents
Farmasoytisk og/eller kosmetisk sammensetning for behandling av lokale adipositter og/eller cellulitt og fremgangsmate for kosmetisk behandling derav Download PDFInfo
- Publication number
- NO331789B1 NO331789B1 NO20035389A NO20035389A NO331789B1 NO 331789 B1 NO331789 B1 NO 331789B1 NO 20035389 A NO20035389 A NO 20035389A NO 20035389 A NO20035389 A NO 20035389A NO 331789 B1 NO331789 B1 NO 331789B1
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- cosmetic
- cellulite
- local
- adipocytes
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 239000002537 cosmetic Substances 0.000 title claims abstract description 14
- 208000035484 Cellulite Diseases 0.000 title claims description 14
- 206010049752 Peau d'orange Diseases 0.000 title claims description 14
- 230000036232 cellulite Effects 0.000 title claims description 14
- 210000001789 adipocyte Anatomy 0.000 title claims description 13
- 238000011282 treatment Methods 0.000 title claims description 13
- 239000000284 extract Substances 0.000 claims abstract description 11
- 235000021508 Coleus Nutrition 0.000 claims abstract description 7
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims description 8
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims description 4
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 241001646851 Coleus Species 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 abstract description 10
- 229940011399 escin Drugs 0.000 abstract description 8
- 229930186222 escin Natural products 0.000 abstract description 8
- 244000194101 Ginkgo biloba Species 0.000 abstract description 7
- 244000061182 Coleus blumei Species 0.000 abstract description 6
- 244000146462 Centella asiatica Species 0.000 abstract description 5
- 235000004032 Centella asiatica Nutrition 0.000 abstract description 5
- 229930003935 flavonoid Natural products 0.000 abstract description 4
- 150000002215 flavonoids Chemical class 0.000 abstract description 4
- 235000017173 flavonoids Nutrition 0.000 abstract description 4
- 150000003648 triterpenes Chemical class 0.000 abstract description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract description 3
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 abstract description 3
- 229940076810 beta sitosterol Drugs 0.000 abstract description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 abstract description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 abstract description 2
- 229950005143 sitosterol Drugs 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 9
- 238000009472 formulation Methods 0.000 description 4
- 241000157280 Aesculus hippocastanum Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 235000010181 horse chestnut Nutrition 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 241001070941 Castanea Species 0.000 description 2
- 235000014036 Castanea Nutrition 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 230000003501 anti-edematous effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- 102000001707 3',5'-Cyclic-AMP Phosphodiesterases Human genes 0.000 description 1
- 108010054479 3',5'-Cyclic-AMP Phosphodiesterases Proteins 0.000 description 1
- RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000781615 Olax dissitiflora Species 0.000 description 1
- 206010036155 Poor peripheral circulation Diseases 0.000 description 1
- NSEWTSAADLNHNH-TXZJYACMSA-N Proanthocyanidin A-2 Natural products C1([C@H]2OC3=C4[C@H]5C6=C(O)C=C(O)C=C6O[C@]([C@@H]5O)(OC4=CC(O)=C3C[C@@H]2O)C=2C=C(O)C(O)=CC=2)=CC=C(O)C(O)=C1 NSEWTSAADLNHNH-TXZJYACMSA-N 0.000 description 1
- 229920002982 Procyanidin A2 Polymers 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 235000006803 Ximenia Nutrition 0.000 description 1
- 241000488894 Ximenia Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 description 1
- 229940011658 asiatic acid Drugs 0.000 description 1
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 description 1
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 description 1
- 229940022757 asiaticoside Drugs 0.000 description 1
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000030632 cutaneous sclerosis Diseases 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- NSEWTSAADLNHNH-UHFFFAOYSA-N pavetannin A-2 Natural products OC1CC2=C(O)C=C3OC(C4O)(C=5C=C(O)C(O)=CC=5)OC5=CC(O)=CC(O)=C5C4C3=C2OC1C1=CC=C(O)C(O)=C1 NSEWTSAADLNHNH-UHFFFAOYSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- NSEWTSAADLNHNH-LSBOWGMISA-N proanthocyanidin A2 Chemical compound C1([C@H]2OC3=C4[C@H]5C6=C(O)C=C(O)C=C6O[C@]([C@@H]5O)(OC4=CC(O)=C3C[C@H]2O)C=2C=C(O)C(O)=CC=2)=CC=C(O)C(O)=C1 NSEWTSAADLNHNH-LSBOWGMISA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- RQIDQEBURXNDKG-MDZDMXLPSA-N ximenic acid Chemical compound CCCCCCCC\C=C\CCCCCCCCCCCCCCCC(O)=O RQIDQEBURXNDKG-MDZDMXLPSA-N 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Child & Adolescent Psychology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
S a m m e n d r a g Det er beskrevet farmasøytiske og/eller kosmetiske sammensetninger som inneholder en kombinasjon av de følgende aktive prinsipper: a) kompleks av escin/beta-sitosterol med fosfolipider, b) kompleks av Gingko biloba dimeriske flavonoider med fosfolipider, c) kompleks av Centella asiatica triterpener med fosfolipider, og eventuelt ett eller begge av: d) etylximeninat, e) Coleus forskolii standardisert ekstrakt.
Description
Foreliggende oppfinnelsen angår en farmasøytisk og/eller kosmetisk sammensetning for behandling av lokale adipositter og cellulitt og en fremgangsmåte for kosmetisk behandling av lokale adipositter og/eller cellulitt.
Lokale adipositter og cellulitt påvirker en stor og økende prosentdel av den vestlige befolkning, i hovedsak kvinner. Cellulitt påvirker også spesielt mange normale vektsammen-satte, voksne kvinner uten fedmeproblemer. Disse problemer er forbundet med pannikulopati tilstanderkarakterisertav dårlig perifersirkulasjon, ødem, fibrose og endret lipo-cyttmetabolisme, og følgelig bør en ideell behandling ta i betraktning alle disse faktorer.
Det store antallet farmasøytiske eller kosmetiske formu-leringer for behandling av lokale adipositter og cellulitt som for tiden er tilgjengelig på markedet har til nå ikke løst problemet med lokale adipositter og cellulitt til-fredsstillende. Nevnte sammensetninger er generelt basert på aktive prinsipper av vegetabilsk opprinnelse, så som eføy, kastanje, colaekstrakter, koffein, beta-adrenergiske stimulerende stoffer, metylxantiner og lignende. Ikke desto mindre har ingen av nevnte sammensetninger til nå vist seg å være effektive, og resultatene som er oppnådd er ofte grunnet diete regimer generelt assosiert med nevnte behandlinger, heller enn grunnet nevnte sammensetninger.
Fra WO 0119158 er det kjent et preparat basert på plante-ekstrakter spesielt egnet for behandling av sirkulasjons-og fedmeproblemer. En sammensetning bestående av bl.a. Ginkgo biloba biflavoner og tørkede ekstrakter av Aesculus hippocastanum og Cantella asiatica er angitt.
Fra US 5194259 er det kjent en sammensetning for topisk administrering til hud inneholdende Ginkgo biloba som en a2-blokker i kombinasjon med minst en annen a2-blokker som fortrinnsvis er escin.
I Reilly W. et al., Redox Report, vol. 5, no. 2/3, 2000, s. 144-145 er det angitt at Centella Asiatica, Aesculus hippocastanum og Vitis vinifera bl.a. er kjent for deres antioksidative egenskaper og deres virkning på bindevevs-metabolisme. Et polyfenolutledet fra Aesculus hippocastanum, proantocyanidin A2, er vist å være en sterkere scavenger av hydrofile HO* radikaler enn a-tokoferol.
Det skal også vises til Bombardelli E. et al., Fitoterapia, vol. 65, no. 1994, s. 387-401 hvorfra er kjent at fytosomer er vegetabilske aktive komponenter kompleksert med fosfolipider .
Det har nå blitt funnet, og dette er målet for foreliggende oppfinnelse, at en farmasøytisk og/eller kosmetisk topisk sammensetning inneholdende en kombinasjon av aktive prinsipper av vegetabilsk opprinnelse gir utmerkede resultater ved behandlingen av lokale adipositter og cellulitt, og som drastisk reduserer kutane fettavleiringer og "appelsinskall" hud, grunnet kombinasjonen av de forskjellige aktiviteter av de forskjellige komponenter, som oppviser anti-ødematøse, antifosfodiesterase, vasokinetiske aktiviteter og fremmer kollagenproduksjon.
Komponentene av sammensetningen ifølge foreliggende oppfinnelse er alle kjente og benyttet i farmasøytiske og/eller i kosmetiske materialer, ikke desto mindre bør det bemerkes at aktiviteten av nevnte enkelte komponenter, når benyttes separert, er mye lavere enn hva som blir oppnådd med sammensetningen ifølge foreliggende oppfinnelse; på den annen side hvor en synergistisk effekt blant nevnte forskjellige komponenter blir observert.
Spesielt gir foreliggende oppfinnelse en farmasøytisk og/eller kosmetisk topisk sammensetning som inneholder som aktive prinsipper escin/beta-sitosterol komplekser med fosfolipider, Gingko biloba dimeriske flavonoidkomplekser med fosfolipider, etylximeninat, Coleus forskolii ekstrakter og Centella asiatica triterpenkomplekser med fosfolipider.
Mer spesielt angår foreliggende oppfinnelse en farmasøytisk og/eller kosmetisk sammensetning inneholdende:
Ekstraktet av Coleus forskolii er et 20 % forskolin standardisert ekstrakt.
Mer spesielt angår foreliggende oppfinnelse en fremgangsmåte for kosmetisk behandling av lokale adipositter og/eller cellulitt, som omfatter påføringen av en sammensetning til områdene som skal behandles.
Escin er et saponin inneholdt i kastanjefrø, og som har bemerkelsesverdige anti-ødematøse egenskaper, trolig grunnet en modifikasjon av den kapillære permeabilitet: det har faktisk blitt vist at escin er i stand til å redusere antallet og diameteren av porene av kapillære veggene gjen-nom hvilke vannutbytting inntreffer. Følgelig er escin-egenskaper betraktet som nyttige ved behandlingen av lokale ødematøse tilstander som er typiske for cellulitt og for lokale adipositter.
Kompleket av escin/beta-sitosteraol med fosfolipider, beskrevet i EP 0 283 713, har samme virkning som escin, men viser en mer forlenget frigjøring av de aktive prinsipper og forbedret biotilgjengelighet.
Komplekset av Gingko biloba dimeriske flavonoider med fosfolipider, beskrevet i EP 0 275 005, har samme aktivitet som de dimeriske Gingko biloba flavoner i fri form, men viser en mer forlenget frigjøring av de aktive prinsipper og bedre biotilgjengelighet. Gingko biloba dimeriske flavonoider er ekstremt kraftige vasoaktive midler grunnet deres inhibitoriske virkning på frigjøringen av histamin og av enzymet cAMP-fosfodiesterase fra mastceller. Inhibering av dette enzym involverer en økning i nivået av cAMP, som er et molekyl som er i stand til å aktivere lipocytt metabolisme. Dette kompleks utøver følgelig en lipolytisk virkning og forbedrer den mikrovaskulære perfusjon og kutanøs trofisme.
Centella asiatica triterpener (asiatinsyre, asiatikosid og madekassinsyre) utøver en gunstig virkning på produksjonen av kollagen (i sin stabile form) av dermale fibroblaster, ved å øke absorpsjonen av hydroksyprolin, som er grunn-leggende for kollagensyntese, for derved å stå i motsetning til den kutane sklerose som er ansvarlig for dannelsen av "appelsinskall hud" som er typisk for cellulitt. Komplekset av Centella asiatica triterpener med fosfolipider beskrevet i EP 0 283 713 gir forlenget frigjøring og bedre penetrering i dermis.
Etylximeninat er etylesteren av ximeninsyre, som er en fettsyre som kan bli funnet i Olax dissitiflora og andre oleaginøse planter av slekten Ximenia. Avanserte kapillaro-skopiske teknikker har vist at etylximeninat har en vesent-lig vasokinetisk aktivietet. Dette kombinert med aktiviteten av de andre aktive prinsipper av formuleringen, er anvendelig ved behandling av cellulitt.
Standardiserte Coleus forskolii- ekstrakt, beskrevet i eksempel 1, inneholder foskolin, som er et velkarakterisert molekyl som er i stand til å stimulere adenylatcyklase-aktivitet og følgelig å øke konsentrasjonen av cykliske nukleotider, som er molekyler som stimulerer lipolyse og blodstrømning ved mikrovaskulært nivå.
Sammensetningene ifølge oppfinnelsen vil bli påført topisk på kroppsområde som er angrepet av lokale adipositter og/eller cellulitt, over tidsperioder som strekker seg fra noen dager til noen måneder, avhenger av alvorligheten av lidelsen som skal behandles, med en frekvens på 1-2 påføringer per dag.
Sammensetningene ifølge oppfinnelsen vil bli formulert, i henhold til konvensjonelle teknikker, i form av krem, olje, gel, skum, emulsjon, melk og lignende, eventuelt innkapslet i liposomer. Nevnte sammensetningene vil inneholde eksi-pientene som vanligvis benyttes i farmasøytisk og/eller kosmetisk teknologi.
Eksempler på formuleringene er angitt nedenfor.
Eksempel 1 - Fremstilling av et 20 % forskolin standardisert ekstrakt av Coleus forskolii 1 kg rizomer og røtter av Coleus forskolii, som er finmalt, blir ekstrahert ved å bruke etter hverandre 10 1 CO2under kontinuerlig recyklisering, i 2 timer ved en temperatur på 45 "C og et trykk på 240 bar. Etter inndampning av opp-løsningsmidlet ved 50 °C, oppløses residuet i 5 volumdeler heksan og tilbake ekstraheres to ganger med 2 volumdeler av 90 % v/v metanol.
Det metanolholdige ekstrakt konsentreres til tørrhet for å oppnå 45 g av et ekstrakt inneholdende 20 % forskolin.
Eksempel 2 - Kremformulering
100 g krem inneholder:
Claims (3)
1. Farmasøytisk og/eller kosmetisk sammensetning inneholdende :
2. Sammensetning ifølge krav 1, hvor ekstraktet av Coleus forskolii er et 20 % forskolin standardisert ekstrakt.
3. Fremgangsmåte for kosmetisk behandling av lokale adipositter og/eller cellulitt, som omfatter påføringen av en sammensetning ifølge krav 1 eller 2 til områdene som skal behandles.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT2001MI001182A ITMI20011182A1 (it) | 2001-06-05 | 2001-06-05 | Composizioni farmaceutiche e/o cosmetiche per il trattamento di adiposita' localizzate e della cellulite |
PCT/EP2002/005390 WO2002098436A1 (en) | 2001-06-05 | 2002-05-16 | Pharmaceutical and/or cosmetic compositions for the treatment of localised adiposities and cellulite |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20035389D0 NO20035389D0 (no) | 2003-12-04 |
NO331789B1 true NO331789B1 (no) | 2012-04-02 |
Family
ID=11447807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20035389A NO331789B1 (no) | 2001-06-05 | 2003-12-04 | Farmasoytisk og/eller kosmetisk sammensetning for behandling av lokale adipositter og/eller cellulitt og fremgangsmate for kosmetisk behandling derav |
Country Status (23)
Country | Link |
---|---|
US (1) | US7476392B2 (no) |
EP (1) | EP1392335B1 (no) |
JP (1) | JP4762492B2 (no) |
KR (1) | KR100869868B1 (no) |
CN (1) | CN100340247C (no) |
AT (1) | ATE360427T1 (no) |
AU (1) | AU2002304632B2 (no) |
CA (1) | CA2449485C (no) |
CY (1) | CY1107672T1 (no) |
CZ (1) | CZ300576B6 (no) |
DE (1) | DE60219782T2 (no) |
DK (1) | DK1392335T3 (no) |
ES (1) | ES2284870T3 (no) |
HK (1) | HK1063295A1 (no) |
HU (1) | HU230348B1 (no) |
IT (1) | ITMI20011182A1 (no) |
NO (1) | NO331789B1 (no) |
PL (1) | PL204550B1 (no) |
PT (1) | PT1392335E (no) |
RU (1) | RU2291683C2 (no) |
SI (1) | SI1392335T1 (no) |
SK (1) | SK287612B6 (no) |
WO (1) | WO2002098436A1 (no) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20021280A1 (it) * | 2002-06-11 | 2003-12-11 | Carlo Ghisalberti | Metodo di trattamento anticellulite |
FR2841470B1 (fr) * | 2002-06-27 | 2006-01-13 | Pharmascience Lab | Utilisation d'isoflavones pour la preparation de compositions topiques utiles pour favoriser l'amincissement et methode de traitement cosmetique associee |
ITMI20031427A1 (it) * | 2003-07-11 | 2005-01-12 | Indena Spa | Combinazioni di agenti vasoattivi, loro uso in campo farmaceutico e cosmetico e formulazioni che li contengono |
ITMI20031428A1 (it) * | 2003-07-11 | 2005-01-12 | Indena Spa | Combinazioni di agenti vasoattivi e loro uso per il trattamento di disfunzioni sessuali |
DE10349979B4 (de) * | 2003-10-24 | 2006-05-18 | Sanofi-Aventis Deutschland Gmbh | Medikamentöse gezielte lokale Lipolyse |
US20050089555A1 (en) * | 2003-10-24 | 2005-04-28 | Aventis Pharma Deutschland Gmbh | Medicinal targeted local lipolysis |
US20050143347A1 (en) * | 2003-12-22 | 2005-06-30 | Aventis Pharma Deutschland Gmbh | Medicinal lipolysis of accumulations of fat |
MX2007007015A (es) * | 2004-12-14 | 2007-07-04 | Menarini Ricerche Spa | Composiciones farmaceuticas para el tratamiento de celulitis. |
EP1849481A4 (en) * | 2005-01-07 | 2012-11-28 | Rohto Pharma | COMPOSITION FOR TOPICAL APPLICATION |
DE102005061071A1 (de) * | 2005-12-21 | 2007-06-28 | Kneipp-Werke Kneipp-Mittel-Zentrale Gmbh & Co. Kg | Wirkstoffkombination aus Santalbinsäure oder Derivate davon und Traubenkernöl zur topischen oder dermatologischen Verwendung |
DE102007007610A1 (de) * | 2007-02-13 | 2008-08-14 | Beiersdorf Ag | Verfahren zur Steigerung der Hautelastizität und/oder eine Stärkung der Spannkraft der Haut |
ITTO20070391A1 (it) * | 2007-06-05 | 2008-12-06 | Medestea Res & Production S P | Composizione di integratore alimentare,farmaco o dispositivo medicale e suo impiego per sopprimere l'appetito, migliorare tono ed umore, con attivita antidepressiva naturale e con effetto antiastenico |
US20120021029A1 (en) * | 2009-04-17 | 2012-01-26 | Lipotec, S.A. | Peptides used in the treatment and/or care of the skin and/or hair and their use in cosmetic or pharmaceutical compositions |
WO2011018763A1 (en) * | 2009-08-12 | 2011-02-17 | Horphag Research Ip (Pyc) Ltd. | Combination of proantocycidins such as pycnogenol or grape seeds and centella asiatica for the treatment of cardiovascular disorders such as atherosclerosis |
DE102009028996A1 (de) * | 2009-08-28 | 2011-03-03 | Rovi Cosmetics International Gmbh | Kosmetische Formulierung zur Reduktion der äußeren Erscheinungsbilder von Cellulite oder Orangenhaut |
FR2962907B1 (fr) * | 2010-07-21 | 2015-05-08 | Ephyla Sas | Extrait de vegetal pour la fabrication de composition amincissante et procede de controle pour mincir mettant en oeuvre une telle composition |
BE1022293B1 (nl) | 2012-11-21 | 2016-03-14 | Wendy Angrave | Methode en composities om toxines te verwijderen uit het lichaam |
KR102267689B1 (ko) | 2013-03-15 | 2021-06-22 | 마리 케이 인코포레이티드 | 화장품 조성물들 및 이의 용도 |
CN103432045B (zh) * | 2013-09-06 | 2015-06-24 | 雅露拜尔生物科技(杭州)有限公司 | 健美瘦身组合物及健美瘦身霜 |
WO2022178967A1 (zh) * | 2021-02-24 | 2022-09-01 | 中国药科大学 | 佛司可林-异佛司可林与五环三萜类化合物的药物组合物及其应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1203515B (it) * | 1987-02-26 | 1989-02-15 | Indena Spa | Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono |
IT1223290B (it) * | 1987-07-27 | 1990-09-19 | Indena Spa | Acidi poliinsaturi ad azione vasocinetica e relative formulazioni farmaceutiche e cosmetiche |
FR2669537B1 (fr) * | 1990-11-28 | 1993-02-19 | Oreal | Composition amincissante a base d'alpha-2-bloqueurs. |
FR2684300B1 (fr) * | 1991-11-29 | 1994-03-11 | Lvmh Recherche | Composition cosmetique ou pharmaceutique, notamment dermatologique, destinee en particulier a favoriser la pigmentation de la peau ou des cheveux, contenant un extrait de ballote, et son procede de fabrication. |
JPH10182473A (ja) * | 1996-12-25 | 1998-07-07 | Lion Corp | 皮下脂肪代謝促進剤及びそれを含む外用組成物 |
US6756065B1 (en) * | 1999-09-10 | 2004-06-29 | Ceteris Holding B.V. | Anti-oxidant preparation based on plant extracts for the treatment of circulation and adiposity problems |
-
2001
- 2001-06-05 IT IT2001MI001182A patent/ITMI20011182A1/it unknown
-
2002
- 2002-05-16 PT PT02732718T patent/PT1392335E/pt unknown
- 2002-05-16 ES ES02732718T patent/ES2284870T3/es not_active Expired - Lifetime
- 2002-05-16 HU HU0400119A patent/HU230348B1/hu not_active IP Right Cessation
- 2002-05-16 SK SK1485-2003A patent/SK287612B6/sk not_active IP Right Cessation
- 2002-05-16 CA CA2449485A patent/CA2449485C/en not_active Expired - Fee Related
- 2002-05-16 EP EP02732718A patent/EP1392335B1/en not_active Expired - Lifetime
- 2002-05-16 CN CNB028112911A patent/CN100340247C/zh not_active Expired - Fee Related
- 2002-05-16 PL PL366914A patent/PL204550B1/pl unknown
- 2002-05-16 DE DE60219782T patent/DE60219782T2/de not_active Expired - Lifetime
- 2002-05-16 SI SI200230545T patent/SI1392335T1/sl unknown
- 2002-05-16 JP JP2003501475A patent/JP4762492B2/ja not_active Expired - Fee Related
- 2002-05-16 WO PCT/EP2002/005390 patent/WO2002098436A1/en active IP Right Grant
- 2002-05-16 AU AU2002304632A patent/AU2002304632B2/en not_active Ceased
- 2002-05-16 AT AT02732718T patent/ATE360427T1/de active
- 2002-05-16 CZ CZ20033293A patent/CZ300576B6/cs not_active IP Right Cessation
- 2002-05-16 KR KR1020037015485A patent/KR100869868B1/ko not_active IP Right Cessation
- 2002-05-16 US US10/477,923 patent/US7476392B2/en not_active Expired - Lifetime
- 2002-05-16 RU RU2003135427/15A patent/RU2291683C2/ru not_active IP Right Cessation
- 2002-05-16 DK DK02732718T patent/DK1392335T3/da active
-
2003
- 2003-12-04 NO NO20035389A patent/NO331789B1/no not_active IP Right Cessation
-
2004
- 2004-08-13 HK HK04106092A patent/HK1063295A1/xx not_active IP Right Cessation
-
2007
- 2007-06-14 CY CY20071100788T patent/CY1107672T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO331789B1 (no) | Farmasoytisk og/eller kosmetisk sammensetning for behandling av lokale adipositter og/eller cellulitt og fremgangsmate for kosmetisk behandling derav | |
AU2002304632A1 (en) | Pharmaceutical and/or cosmetic compositions for the treatment of localised adiposities and cellulite | |
CA2588131C (en) | Method and composition for reducing the appearance of wrinkles | |
WO2008139182A2 (en) | Skin care composition | |
CN115089536A (zh) | 一种强化抗老效果的保湿面霜及其制备方法 | |
US20040126351A1 (en) | Topical composition having natural skin anti-irritant ingredient and method of use | |
NO334186B1 (no) | Farmasøytiske og kosmetiske sammensetninger mot aldring av hud | |
Baldi et al. | Synergistic use of bioactive agents for the management of different skin conditions: an overview of biological activities. | |
KR100517465B1 (ko) | 아토피 피부용 한방 화장료 조성물 | |
JPH09241146A (ja) | 皮膚外用剤 | |
JP4964590B2 (ja) | 血管作用剤の組合せ物、それらの薬剤および化粧品分野での使用、ならびにそれらを含む製剤 | |
CN106137875B (zh) | 一种组合物及面膜 | |
CN114209632B (zh) | 一种预洗固发精油 | |
CN111973523A (zh) | 一种马齿苋抗敏修护面膜及其制备方法 | |
KR101477073B1 (ko) | 인삼종자 추출물을 포함하는 피부 미백용 화장료 조성물 | |
JP2001187742A (ja) | テストステロン−5α−レダクターゼ阻害剤 | |
KR102475898B1 (ko) | 그라비올라 항균 추출물을 함유하는 화장료 조성물 및 그 제조방법 | |
JP2015508815A (ja) | Cpt−1調節剤及びその組成物としてのスターフルーツ抽出物の使用 | |
KR101566694B1 (ko) | 인삼종자 추출물의 수율을 증가시키는 방법 | |
EP4366728A1 (en) | Compositions for treatment of diabetic symptoms | |
KR20170137554A (ko) | 복합 생약 추출물을 포함하는 피부 개선용 조성물 | |
MX2007007642A (en) | Method and composition for reducing the appearance of wrinkles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |